CN100427074C - Medicine for treating fatty liver - Google Patents

Medicine for treating fatty liver Download PDF

Info

Publication number
CN100427074C
CN100427074C CNB2006100772939A CN200610077293A CN100427074C CN 100427074 C CN100427074 C CN 100427074C CN B2006100772939 A CNB2006100772939 A CN B2006100772939A CN 200610077293 A CN200610077293 A CN 200610077293A CN 100427074 C CN100427074 C CN 100427074C
Authority
CN
China
Prior art keywords
medicine
parts
weight portions
liver
rhizoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2006100772939A
Other languages
Chinese (zh)
Other versions
CN1876160A (en
Inventor
张忠
张洪波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB2006100772939A priority Critical patent/CN100427074C/en
Publication of CN1876160A publication Critical patent/CN1876160A/en
Application granted granted Critical
Publication of CN100427074C publication Critical patent/CN100427074C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention discloses a medicine for treating fatty liver, which is prepared from 85 to 100 weight portions of milkvetch root, 70 to 95 weight portions of largehead atractylodes rhizome, 70 to 95 weight portions of atractylodes rhizome, 80 to 100 weight portions of water plantain, 70 to 95 weight portions of polyporus, 70 to 90 weight portions of tuckahoe, 60 to 75 weight portions of rhubarb, 60 to 80 weight portions of weeping forsythia capsule, 45 to 60 weight portions of common prism tuber, 45 to 60 weight portions of zedoray rhizome, 65 to 80 weight portions of hawthorn fruit, 55 to 70 weight portions of lotus leaf and 45 to 60 weight portions of cassia bark. The effective rate of the medicine of the present invention is 97%, the healing rate is 66%, and the effective rate and the healing rate of the medicine of the present invention are obviously improved higher than that of the existing medicines. The medicines for treating both manifestation and root causes of diseases are selected, the medicines are selected to treat root causes of diseases according to the traditional Chinese medicine theory, and the medicines are selected to treat manifestation causes of diseases according to the modern medicine theory. The medicine of the present invention pays attention to strengthening healthy qi, and positive strong evil is automatically eliminated. The medicine properties are soft, the adopted medicines are agents for gradually disappearing and slowly dispersing, and the medicine effect is slowly penetrated into the disease evil. The medicine of the present invention has the advantages of no toxic or side effect, no disadvantages when the medicine is taken for a long term, high safety, reliability, simple preparation, low cost, convenient administration, portability and convenient popularization.

Description

A kind of medicine for the treatment of fatty liver
Technical field
The present invention relates to a kind of Chinese medicine, is a kind of medicine for the treatment of fatty liver specifically.
Background technology
Liver is the vitals of lipid metabolism, when liver fat metabolism generation obstacle, causes the dynamic equilibrium imbalance of lipid material, fat is accumulated in hepatocyte too much, the amount of storing up surpasses liver weight more than 5%, or when the histology has 50% above hepatocyte fatization, promptly is called fatty liver.Epidemiological study shows, fatty liver both can by drink, fat, also can be by gestation, medicine, poisoning, malnutrition, diabetes, hepatitis virus or the infection of other source of disease bodies, and inborn errors of metabolism etc. causes.The pathogenesis of fatty liver rate is more than 10%, male's fatty liver is obviously more than the women below 45 years old, there was 20% people to suffer from various degree fatty liver in 30 years old among the male of the left and right sides, the 75-90% alcoholic has fatty liver, the existing rejuvenation trend of alcoholic fatty liver morbidity, and tangible industry characteristic is arranged, dinner party at ordinary times, the 30-40 year male who often participates in " the intestines and stomach enlarge have a dinner party " belongs to the group of people at high risk, and especially severe overweight people fatty liver incidence rate is up to 61-90%.Up to 46.7%, this fatty liver recall rate 43.1% to the simple Obese children of Obesity Clinic is similar in school Obese children pathogenesis of fatty liver rate, and prevalence of overweight children fatty liver recall rate is 12.8%, apparently higher than normal type child 0.7%.Fatty liver was Hesperian commonly encountered diseases originally., reach preventive measure and relatively lag behind because living standard in recent years improves, and dietary structure changes in China, the pathogenesis of fatty liver rate increases sharply, and has become the second largest hepatopathy that is only second to hepatitis B.Age of onset is more and more littler, becomes the harm people able-bodied commonly encountered diseases, and also becomes one of hepatic fibrosis regulating liver-QI disease in hardened main early stage.Seek highly effective and safe treatment fatty liver medicine and become extremely urgent vital task.
The fatty liver ownership traditional Chinese medical science " long-pending disease ", " liver addiction "." interior warp " cloud: " liver is long-pending, day lump at the left hypochondrium ", Chinese medicine is thought, lump at the left hypochondrium just is meant that significant quantities of fat piles up hepatocyte, blocks in liver, so that hepatic dysfunction, catharsis is obstructed, the lifting dereliction of duty, and perverse and unreasonable manner takes advantage of spleen to violate stomach, cause spleen fortune to lose key again, wet consor expectorant causes the stasis of blood by expectorant, stay and do not go, QI and blood, expectorant be turbid, the knot of fighting mutually, poly-stagnating to long-pending, cause hepatosplenomegaly, stagnant phlegm-damp is real, runs through fatty liver all the time.The fatty liver position is liver, and right normal liver spleen is with sick, and is relevant with kidney again, because of " The liver and the kidney have a common source ", be again mother child relation, the kidney being the origin of congenital constitution, in occupy nephroyin and nephroyang, the catharsis of liver, the fortuneization of the spleen, rely on kidney qi invariably and agitate, if deficiency of kidney-QI, deficiency of kidney yang, it is too late to gasify, phlegm-turbidity and blood stasis stagnates more, so kidney is the root of expectorant, spleen is the source of expectorant.Liver spleen two is dirty, and is mutually biochemical, mutual restriction, and the physiology co-relation is close, influences each other on the pathology, and wood needs soil flourish, and soil needs wood to dredge, and wood is born in water and is longer than soil, rustic dash and then wooden luxuriant, native Rong Ze wood is not strongly fragrant.Do not rise as lunar, then wood gas does not fall into, and wood gas sink, irritability stasis then, and its disease being located in the liver, it is at spleen.
Summary of the invention
The object of the present invention is to provide a kind of medicine for the treatment of fatty liver, it can regulate the balance of health own, treats fatty liver from its morbidity root.
The routine clinical verification through more than 20 years several thousand, fatty liver are a kind of reversibility diseases, and pharmaceutical formulation of the present invention is basis of treatment to remove the cause of disease, by wet activating the spleen, soothing the liver dissipating blood stasis; And be aided with the symptomatic drugs liver-protecting fat-dropping and control its mark.Tonifying the spleen one method, the treatment that runs through fatty liver also are treatment fatty liver key points all the time; Excess syndrome does not have soil and stops up the strongly fragrant void of wood; Excess syndrome is QI and blood source abundance then; The liver body gets its nourishing and it uses self-regulated, and in this respect, Zhong Shi accuses really earnestly and tirelessly: " know the disease of liver, knowing the liver disease will be transmitted into the spleen is worked as earlier tonifying the spleen.”
Medicine of the present invention is made by following parts by weight raw material:
Radix Astragali 85-100 part, Rhizoma Atractylodis Macrocephalae 70-95 part, Rhizoma Atractylodis 70-95 part, Rhizoma Alismatis 80-100 part, Polyporus 70-95 part, Poria 70-90 part, Radix Et Rhizoma Rhei 60-75 part, Fructus Forsythiae 60-80 part, rhizoma sparganic 45-60 part, Rhizoma Curcumae 45-60 part, Fructus Crataegi 65-80 part, Folium Nelumbinis 55-70 part, Cortex Cinnamomi 45-60 part.
Said medicine natural drying or oven dry are pulverized the back with 80-100 mesh sieve mesh screen mistake, and be encapsulated, and every heavy 0.5 gram is obeyed the 5-6 grain at every turn, obeys every day 3 times, and 2 months was 1 course of treatment.Or make the watered pill, and obey 6 grams at every turn, obey every day 3 times, also can be made into honeyed pill, every ball weighs 12 grams, obeys 1 ball at every turn, obeys every day 3 times.
The further scheme of said medicine is:
95 parts of the Radixs Astragali, 90 parts of the Rhizoma Atractylodis Macrocephalaes, 80 parts of Rhizoma Atractylodis, 95 parts of Rhizoma Alismatis, 85 parts of Polyporus, 85 parts in Poria, 65 parts of Radix Et Rhizoma Rhei, 76 parts of Fructus Forsythiaes, 55 parts of rhizoma sparganic, 55 parts of Rhizoma Curcumae, 77 parts of Fructus Crataegis, 65 parts on Folium Nelumbinis, 55 parts of Cortex Cinnamomis.
The effect of this every flavor medicine of filling a prescription:
Radix Astragali sweet in the mouth is warm in nature, the QI invigorating the lucid yang sending up, and spleen reinforcing is good for the stomach, and enzyme, blood sugar lowering fall in hepatoprotective, and hormone-like effect is arranged, and regulate immunologic function, increase the hepatocyte immunizing potency.
Rhizoma Atractylodis Macrocephalae sweet-bitter flavor, invigorating the spleen and replenishing QI, soil are wet actually, and Tu Wang then clearing heat in QI system rises and gives on precise and tiny from falling, and turbid yin descends and defeated under the waste matter, hepatoprotective, falls enzyme, blood sugar lowering, the various fatty livers of wide clinical application.
Rhizoma Atractylodis acrid in the mouth hardship is apt to separate damp, rises then spleen invigorating, falls then stomach function regulating, mends fortune and holds concurrently mutually, and enzyme, blood sugar lowering fall in relieving distension by promoting circulation of QI, hepatoprotective, especially with better to the fatty liver curative effect of the turbid heap soil or fertilizer over and around the roots Sheng of the fertile expectorant of body.
Rhizoma Alismatis is sweet light cold in nature, and the logical internal organs of a surname are wet, and diuretic removes long-pending, go turbid, long-pending turbid going, the spleen kidney must be mended, microcirculation improvement improves liver blood flow, thereby improves liver metabolism, promotes fat in the liver oxidation and blood fat reducing content, cholesterol reducing.
The Polyporus slightly sweet flavor is flat, eliminating dampness and diuresis, and enzyme falls in hepatoprotective, improves liver function, strengthens the histiocyte immunologic function.
The Poria slightly sweet flavor is flat, lightly seasoned sharp key, and sweet pursuing with supporing yang, sweet flat YANG invigorating, strengthening the spleen wet, and is the panacea of dehumidifying.Enzyme falls in hepatoprotective, and hepatocyte is had protective effect, and glutamate pyruvate transaminase ALT is descended, and can prevent hepatic necrosis, promotes the cell humoral immune function.
The Radix Et Rhizoma Rhei bitter in the mouth is cold in nature, and is bitter stagnant to let out, and removes old dirt and settling five organs, increases gastrointestinal peristalsis, cleanses the intestines and stomach, promoting lipid to discharge, is benefit to lead to, and the spleen invigorating function of gallbladder promoting increases bile secretion, antiinflammatory, enzyme falls in hepatoprotective, and cholesterol reducing suppresses hepatic fibrosis, prevents that liver cirrhosis from taking place and development.And can strengthen histiocytic permeability, enhancing immunity, fat-reducing.
The Fructus Forsythiae bitter in the mouth is slightly cold, heat-clearing and toxic substances removing, and dispersing swelling and dissipating binds, anti-liver damages, enzyme falls in hepatoprotective, quickens liver swelling cell and disappears, and reduces hepatocellular balloon sample change regulating liver-QI cytolipin and drips, promote glycogen and ribonucleic acid to recover, reduce glutamate pyruvate transaminase ALT vigor, the treatment of the various hepatopathy of clinical application.
The rhizoma sparganic bitter in the mouth is flat, blood-activating and qi-promoting, and the removing food stagnancy pain relieving stops hepatic fibrosis.
The Rhizoma Curcumae bitter in the mouth is flat, and it is long-pending to change the fat mill, and the blood clotting of cooling down stagnates, and treats hepatosplenomegaly.
Fructus Crataegi sour in the mouth tepor, it is long-pending to change the fat mill, and promoting blood circulation to remove blood stasis can alleviate the deposition of lipid at organ, and enzyme falls in hepatoprotective, and it is synthetic to suppress cholesterol, and anti-fatty liver can be used for the fatty liver that a variety of causes causes.
The Cortex Cinnamomi acrid in the mouth is warm in nature, and then current are wet dispels for a surname's gas that activates yang, the kidney warming activating QI, beneficial fire.
The Folium Nelumbinis bitter in the mouth is flat, and sending up the lucid YANG is amusing, and resolving phlegm lowering turbidity has the disappear effect of fat of better fat-reducing.
This prescription: desire out its arteries and veins and open its stasis of blood earlier and stagnate, desire out its stasis of blood and stagnate and transfer its mechanism of qi earlier; Desire to fall earlier sharp its phlegm-damp of its fat, desire the principle of earlier strong its taste of sharp its phlegm-damp, the irritability bar is reached, the liver network does not have the trouble of stasis of blood resistance, and fat does not have the evil of accumulation; The strong fortune of spleen soil, phlegm-damp does not have the source that grows; Kidney qi must be filled, and mechanism of qi a surname lead to, and blood vessels are freely sharp, crystal's four cloth, and the damp-phlegm stasis of blood must be removed, and the turbid difficulty of fat is coagulated, then its sick difficult one-tenth.
Medicine advantage of the present invention is: 1, medicine effective percentage of the present invention is 97%, and cure rate is 66%, apparently higher than existing medicine.See Table 1.2, medicine is selected at the specimen two ends, in property strong, except selecting medicine to effect a permanent cure by the Chinese medicine theory; Select medicine to take stopgap measures according to modern pharmacology again.3, pay attention to setting upright, just strong evil from removing.4, the property of medicine is gentle, has no side effect, and the no fraud of clothes is safe and reliable for a long time.5, preparation is simple, economic, takes, assists band convenient, is convenient to promote.6, the medicine of Cai Yonging all is the slow diffusing agent that fades, and drug effect slowly infiltrates into pathogenic factor.
Clinical trial:
In April, 2002-2005 time year December
Patient selection standard: select outpatient's 200 examples,, be divided into treatment group and matched group at random, every group of each 100 routine patient in 1: 1 ratio.
Diagnosis basis: all cases all possess following 5 conditions, 1. body obesity, and the history of being addicted to drink, or history of virus hepatitis is arranged.2. liver increases, the matter medium hardness.3. glutamate pyruvate transaminase, Moschus moschiferous are turbid, the Moschus moschiferous wadding is light or moderate is unusual.4. blood fat obviously increases.5. ultrasound diagnosis prompting liver increases.
100 examples are organized in treatment, wherein: age 27-60 year, 39.8 years old mean age; Male's 86 examples, women's 14 examples; The course of disease 6 months-9 years, average 4.5 years; History of virus hepatitis 36 examples are arranged, alcoholic 93 examples, splenomegaly person's 48 examples, hepatic fibrosis person's 15 examples, companion's glycosuria patient 12 examples.
Matched group 100 examples, wherein: age 26-62 year, 38.9 years old mean age; Male's 90 examples, women's 10 examples; The course of disease 8 months-10 years average 4.3 years, has history of virus hepatitis person's 37 examples, alcoholic 91 examples, splenomegaly person's 46 examples, hepatic fibrosis person's 13 examples, companion's glycosuria patient 10 examples.
Two groups of most of patients have the different obesity of degree, weak, loss of appetite, abdominal distention, hypochondriac pain, feel sick, Yuan gas, wherein jaundice appears in minority.
At two groups of ages, sex, the course of disease, the state of an illness, medical history are similar, and all do not have significant difference (P>0.05) between group, have comparability.
Therapeutic Method: the treatment group adopts medicine of the present invention, obeys 5 of capsules at every turn, obeys every day 3 times, and 2 months was 1 course of treatment, obeyed 3 courses of treatment continuously.Matched group clothes Western medicine fenofibrate, 1 of every day, 2 months was 1 course of treatment, also obeyed 3 courses of treatment continuously.Take medicine for two groups and withdraw other medicines therebetween, check contrast after taking the course of treatment.
Two groups of medications were observed symptom and sign 1 time in per 20 days therebetween; Check liver function every month 1 time, and do ultrasound diagnosis.After taking 3 courses of treatment, carry out comprehensive review, judge curative effect.
Curative effect determinate standard: judge curative effect, index has following 5: 1. liver bounces back to normally.2. liver function recovery is normal.3. blood fat is all reduced in normal range.4. ultrasound diagnosis fatty liver ultrasonogram recovers normal.5. clinical symptom disappearance.
Recovery from illness: after treating 3 courses of treatment (6 months), 5 curative effect index all reach.
Produce effects: in 5 indexs, reach 3-4 item person.
Effectively: in 5 indexs, reach 2 persons.
Invalid: as in 5 indexs, to reach 1 or do not have the changer.
Table 1 medicine clinical efficacy of the present invention synopsis
Two groups of total effective rates: the treatment group is 97%; Matched group is 88%.No significant difference (P>0.05).Cure rate: the treatment group is 66%; Matched group is 28%, and there were significant differences (P<0.05)
Medical record is given an example:
Example 1: Liu Zhenhua, the man, 43 years old, the cook, on April 28th, 2002 went to a doctor.
Patient's height 180cm, body weight 95kg was engaged in food and drink work 18 years, had a liking for the good wine of cigarette usually, checked before 5 years to be fatty liver, and hepatalgia does not draw attention.Existing spiritlessness and weakness, pale complexion, big loose stool, no mucus, gastral cavity abdomen painful abdominal mass expands, and if any the thing infraction, pale tongue is fat to have tooth to print, white and greasy fur, the deep pulse jewelry, expensive clothing and other valuables are unable.Lab testing: glutamate pyruvate transaminase 122IU/L (normal 10--40IU/L), triglyceride 9.5mmol/L (normal 0.4-1.70mmol/L), cholesterol 8.8mmol/L (normal 3.0-5.20mmol/L).The B ultrasonic prompting: the liver body increases, 6.5cm under the xiphoid-process, and 4cm under the right rib, luminous point is intensive in the liver, echo attenuation, it is pure that margo anterior hepatis becomes, and the interior vascular of liver shows unclear, is diagnosed as severe fatty liver.Comprehensive analysis to both pulse condition and symptoms, this is a weakness of the spleen and stomach, contains in the phlegm-damp, throws 3 courses of treatment of medicine of the present invention, six months altogether, checks after taking the medicine course of treatment: clinical symptoms, sign all disappears, and glutamate pyruvate transaminase, triglyceride, cholesterol are all reduced in normal range.The B ultrasonic prompting, the liver size is normal, and echo is even, and it is clear that blood vessel moves towards, and liver fat ultrasonogram disappears, and reaches the clinical cure standard.Follow up a case by regular visits to after 1 year, do not see recurrence.
Example 2: the prosperous army of battle array, the man, 34 years old, the veterinary, on July 12nd, 2003 went to a doctor.
Patient's obesity has the tobacco and wine of having a liking for history, and right repeatedly flank distending pain was had a surplus in 10 years, and extremity are aching and limp, spirit is tired, and are sleepy constantly, dizzy feeling of fullness in the head, and nervous cardiopalmus, moving then asthma has 1 month, body of the tongue is dim partially, and sees petechia, and thick fur is bored with in vain, stringy and rolling pulse.Laboratory is looked into: first, second, third, fourth, penta type hepatopathy, antigen are all positive, glutamate pyruvate transaminase 132IU/L, triglyceride 8.6mmol/L, cholesterol 9.3mmol/L.B ultrasonic shows: liver enlargement, margo anterior hepatis become pure, see a large amount of decaying waves of liver back segment, and vascular shows unclear in the liver: CT scan prompting, severe fatty liver.Comprehensive analysis to both pulse condition and symptoms is to accumulate in the turbid damp, and the expectorant stasis of blood is handed over resistance.Throw 3 courses of treatment of medicine of the present invention, check after totally 180 days, the 13kg that loses weight, blood fat, liver function, chemical examination are all normal; The B ultrasonic check: ultrasonography of liver is normal, clinical cure.Follow up a case by regular visits to after 1 year, stable curative effect does not have unusual uncomfortable.
Example 3: Hao Jia, the woman, 35 years old, accounting, on February 18th, 2004 went to a doctor.
The patient felt weak over 1 year, and oil, dull pain in liver are detested in dizzy hyperhidrosis, and more so, big loose stool accompanies indigestion food every day 3-4 time after the fatigue, and the light amount of menstruation color is few, pyknic type, and shallow complexion, pale tongue, there is petechia on the tip of the tongue, tongue limit, thready and hesitant pulse.Lab testing: glutamate pyruvate transaminase 124IU/L, triglyceride 6.2mmol/L, cholesterol 9.6mmol/L.The B ultrasonic prompting: 4.2cm under the liver rib, 3.7cm under the xiphoid-process, margo interior hepatis become pure, and the liver inner structure is fuzzy, and the nearly sound of echo strengthens, and acoustic attenuation far away is diagnosed as fatty liver, comprehensive analysis to both pulse condition and symptoms, damp-retention due to hypofunction of the spleen, expectorant stasis of blood alternate, the liver failing to maintain the normal flow of QI are stopped up resistance liver network.Throw 3 courses of treatment of medicine of the present invention, check after taking the course of treatment: liver function, blood fat, cholesterol are all normal.B ultrasonic shows: the degeneration of liver fat-like disappears, and follows up a case by regular visits to after 1 year, does not have uncomfortable and unusual.
The specific embodiment
Embodiment 1: 95 parts of the Radixs Astragali, 90 parts of the Rhizoma Atractylodis Macrocephalaes, 80 parts of Rhizoma Atractylodis, 95 parts of Rhizoma Alismatis, 85 parts of Polyporus, 85 parts in Poria, 65 parts of Radix Et Rhizoma Rhei, 76 parts of Fructus Forsythiaes, 55 parts of rhizoma sparganic, 55 parts of Rhizoma Curcumae, 77 parts of Fructus Crataegis, 65 parts on Folium Nelumbinis, 55 parts of Cortex Cinnamomis.
Embodiment 2: 85 parts of the Radixs Astragali, 75 parts of Rhizoma Atractylodis, 80 parts of the Rhizoma Atractylodis Macrocephalaes, 85 parts of Rhizoma Alismatis, 75 parts of Polyporus, 75 parts in Poria, 65 parts of Radix Et Rhizoma Rhei, 60 parts of Fructus Forsythiaes, 45 parts of rhizoma sparganic, 45 parts of Rhizoma Curcumae, 65 parts of Fructus Crataegis, 55 parts on Folium Nelumbinis, 45 parts of Cortex Cinnamomis.
Embodiment 3: 90 parts of the Radixs Astragali, 80 parts of Rhizoma Atractylodis, 85 parts of the Rhizoma Atractylodis Macrocephalaes, 80 parts of Rhizoma Alismatis, 80 parts of Polyporus, 70 parts in Poria, 70 parts of Radix Et Rhizoma Rhei, 65 parts of Fructus Forsythiaes, 50 parts of rhizoma sparganic, 50 parts of Rhizoma Curcumae, 70 parts of Fructus Crataegis, 60 parts on Folium Nelumbinis, 50 parts of Cortex Cinnamomis.
Embodiment 4: 95 parts of the Radixs Astragali, 80 parts of Rhizoma Atractylodis, 95 parts of the Rhizoma Atractylodis Macrocephalaes, 90 parts of Rhizoma Alismatis, 95 parts of Polyporus, 80 parts in Poria, 75 parts of Radix Et Rhizoma Rhei, 70 parts of Fructus Forsythiaes, 55 parts of rhizoma sparganic, 55 parts of Rhizoma Curcumae, 75 parts of Fructus Crataegis, 65 parts on Folium Nelumbinis, 55 parts of Cortex Cinnamomis.

Claims (2)

1, a kind of medicine for the treatment of fatty liver is characterized in that: medicine of the present invention is made by following parts by weight crude drug:
Radix Astragali 85-100 part, Rhizoma Atractylodis Macrocephalae 70-95 part, Rhizoma Atractylodis 70-95 part, Rhizoma Alismatis 80-100 part, Polyporus 70-95 part, Poria 70-90 part, Radix Et Rhizoma Rhei 60-75 part, Fructus Forsythiae 60-80 part, rhizoma sparganic 45-60 part, Rhizoma Curcumae 45-60 part, Fructus Crataegi 65-80 part, Folium Nelumbinis 55-70 part, Cortex Cinnamomi 45-60 part.
2, the medicine of treatment fatty liver according to claim 1 is characterized in that: medicine of the present invention is made by following parts by weight crude drug:
95 parts of the Radixs Astragali, 90 parts of the Rhizoma Atractylodis Macrocephalaes, 80 parts of Rhizoma Atractylodis, 95 parts of Rhizoma Alismatis, 85 parts of Polyporus, 85 parts in Poria, 65 parts of Radix Et Rhizoma Rhei, 76 parts of Fructus Forsythiaes, 55 parts of rhizoma sparganic, 55 parts of Rhizoma Curcumae, 77 parts of Fructus Crataegis, 65 parts on Folium Nelumbinis, 55 parts of Cortex Cinnamomis.
CNB2006100772939A 2006-04-24 2006-04-24 Medicine for treating fatty liver Expired - Fee Related CN100427074C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2006100772939A CN100427074C (en) 2006-04-24 2006-04-24 Medicine for treating fatty liver

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2006100772939A CN100427074C (en) 2006-04-24 2006-04-24 Medicine for treating fatty liver

Publications (2)

Publication Number Publication Date
CN1876160A CN1876160A (en) 2006-12-13
CN100427074C true CN100427074C (en) 2008-10-22

Family

ID=37508830

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2006100772939A Expired - Fee Related CN100427074C (en) 2006-04-24 2006-04-24 Medicine for treating fatty liver

Country Status (1)

Country Link
CN (1) CN100427074C (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101401918B (en) * 2008-11-06 2011-06-01 韩海林 Chinese medicinal composition for treating fatty liver
CN107029065A (en) * 2017-04-14 2017-08-11 吴冬梅 Hypoglycemic decoction

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1586611A (en) * 2004-09-23 2005-03-02 内蒙古伊泰医药科技开发有限责任公司 Preparation of granular powder for treating hepatitis and quality control method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1586611A (en) * 2004-09-23 2005-03-02 内蒙古伊泰医药科技开发有限责任公司 Preparation of granular powder for treating hepatitis and quality control method

Also Published As

Publication number Publication date
CN1876160A (en) 2006-12-13

Similar Documents

Publication Publication Date Title
CN1321680C (en) Chinese medicine composition for treating gastritis, gastric ulcer and duodenal ulcer
CN102205107B (en) Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof
CN103099959B (en) Traditional Chinese medicine preparation for treating ulcerative colitis and preparation method thereof
CN103301412A (en) Traditional Chinese medicine composition for treating alcoholic liver
CN101797326A (en) Chinese materia medica preparation for treating borborygmus diarrhoea and preparation method thereof
CN102205108B (en) Traditional Chinese medicine preparation for treating gastric ulcer and preparation method thereof
CN103041360B (en) Oral liquid for treating functional diarrhea and irritable bowel syndrome
CN104958607A (en) Traditional Chinese medicine composition for treating burning mouth syndromes of climacteric women and preparation method thereof
CN102526670B (en) Traditional Chinese medicinal composition for treating cholecystitis and preparation method thereof
CN101953936A (en) Traditional Chinese medicine preparation for treating immune thrombocytopenia and preparation method thereof
CN103041256A (en) Chinese herb preparation for curing recurrent respiratory tract infection of children
CN105497816A (en) Traditional Chinese medicine preparation for treating atherosclerosis and preparation method thereof
CN101607067B (en) Traditional Chinese medicine preparation for treating cholelithiasis and preparation method thereof
CN100427074C (en) Medicine for treating fatty liver
CN101658656B (en) Medicine for curing cholelithiasis
CN104367753A (en) Traditional Chinese medicine composition for treating type 2 diabetes
CN102961688A (en) Traditional Chinese medicine decoction capable of reducing alpha fetoprotein and preventing and treating liver cancer
CN107412508A (en) A kind of Chinese medicine composition of dredging vascellum
CN100534507C (en) Oral Chinese traditional medicine composition for treating chronic enteritis
CN104352851A (en) Chinese medicinal honeyed pills for preventing and treating pancreatitis and preparation method for Chinese medicinal honeyed pills
CN103721186B (en) A kind of medicine yellow wine for the treatment of diabetes and climacteric syndrome and preparation method thereof
CN102335399B (en) Chinese medicinal composition for treating liver cirrhosis in early stage
CN106692858A (en) Medicine for treating threatened abortion and preparation method of medicine
CN104940777A (en) Electuary capable of treating liver-yang hyperactivity and spleen weakness type diarrhea during menstruation and preparation method thereof
CN103191277B (en) Traditional Chinese medicine decoction for treating gall stones caused by syndrome of qi stagnation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081022